The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes And Clovis

For Immediate Release

Chicago, IL –February 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Intercept (NASDAQ:ICPT) , Gilead Sciences, Inc. (NASDAQ:GILD) , Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) , Alkermes plc (NASDAQ:ALKS) and Clovis Oncology (NASDAQ:CLVS) .

Here are highlights from Wednesday’s Analyst Blog:

Biotech Stock Roundup: ICPT, GILD, VRTX and More

As we approach the tail end of earnings results, regular pipeline updates and data read outs take centerstage in the biotech sector. Key among those include Intercept, which surges on the back of positive data from the phase III trial on NASH drug, and Vertex, which too reports favorable outcomes on Symdeko.

Recap of the Week’s Top Stories:

Intercept Soars on NASH Drug Trial Results: Shares of Intercept Pharmaceuticals jumped after the company announced upbeat findings from its late stage study — REGENERATE — of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). The study results show that once-daily OCA 25 mg met the primary endpoint of fibrosis improvement (≥1 stage) without any worsening signs of NASH during the planned 18-month interim analysis. Moreover, a greater proportion of patients under both OCA treatment arms compared with placebo achieved the primary endpoint of NASH resolution with no deterioration of liver fibrosis noticed even though the evaluation did not reach any statistical significance.

Nevertheless, the study was required to attain one of the two primary goals per the FDA which it did. Intercept intends to file for regulatory approval in the United States and Europe in the second half of 2019. The news significantly boosted investor sentiments given the market potential of NASH and the fact that biotech bigwig Gilead Sciences, Inc. announced the failure of a late-stage study on selonsertib involving patients with compensated cirrhosis (F4) due to NASH. This in turn, puts Intercept ahead in the race to get a drug approved for NASH.

Vertex Reports Positive Data on Symdeko: Vertex Pharmaceuticals Inc. announced that the late-stage study on Symdeko, conducted in Europe and Australia, was successful. The phase III study was performed on children aged 6 to 11 years with cystic fibrosis (CF), who have either two copies of the F508del mutation or a single one of the F508del mutation and one residual function mutation. The study met its primary endpoint of absolute change in lung clearance index (LCI2.5) through an 8-week regime as it demonstrated a statistically significant improvement in LCI2.5 among patients treated with Symdeko. The investigation was under way to seek Symdeko’s label expansion for the patient population enrolled in Europe. We note that Vertex had earlier submitted an sNDA to the FDA for Symdeko, based on a previously completed phase III safety study on 6-11 year-old children in the United States and Canada.

Gilead Clinches Approval for Yescarta in Canada: Gilead Sciences notified that Health Canada has granted a Notice of Compliance (NOC) to chimeric antigen receptor T (CAR T) cell therapy, Yescarta axicabtagene ciloleucel). The therapy has been approved for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma and DLBCL, arising from follicular lymphoma (transformed follicular lymphoma, or TFL).

Alkermes Collaborates With Clovis: Alkermes plc entered into a research collaboration pact with Clovis Oncology. Both companies will evaluate ALKS 4230, Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, combined with Rubraca — Clovis' approved PARP inhibitor — and lucitanib, Clovis' investigational tyrosine kinase inhibitor. Per the terms of the agreement, Alkermes and Clovis will perform preclinical studies to examine the mechanism of action and efficacy of the combinations of ALKS 4230 with Rubraca and ALKS 4230 with lucitanib on multiple tumor models. Both entities will share costs related to the preclinical probes.

Alkermes currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.